Enquiries to Ministry of Health 0800 855 066

APPLICATION FOR SUBSIDY BY SPECIAL AUTHORITY

Page 1 Form SA2453 August 2025

APPLICANT (stamp or sticker acceptable)	PATIENT NHI:	REFERRER Reg No:		
Reg No:	First Names:	First Names:		
Name:	Surname:	Surname:		
Address:	DOB:	Address:		
	Address:			
Fax Number:		Fax Number:		
Bevacizumab				
Initial application — unresectable hepatocellular carcinoma Applications from any relevant practitioner. Approvals valid for 6 months. Prerequisites (tick boxes where appropriate) Patient is currently on treatment with bevacizumab, and met all remaining criteria prior to commencing treatment or Patient has locally advanced or metastatic, unresectable hepatocellular carcinoma Patient has preserved liver function (Child-Pugh A) and Transarterial chemoembolisation (TACE) is unsuitable and Patient has not received prior systemic therapy for the treatment of hepatocellular carcinoma or Patient received funded lenvatinib before 1 March 2025 Patient has experienced treatment-limiting toxicity from treatment with lenvatinib and Patient has an ECOG performance status of 0-2 To be given in combination with atezolizumab				
Current approval Number (if known):				
Applications from any relevant practitioner. Approvals valid for 6 months. Prerequisites(tick box where appropriate)				
There is no evidence of disease progression				

Enquiries to Ministry of Health 0800 855 066

APPLICATION FOR SUBSIDY BY SPECIAL AUTHORITY

Page 2 Form SA2453 August 2025

APPLICANT (stamp or sticker acceptable)	PATIENT NHI:	REFERRER Reg No:		
Reg No:	. First Names:	First Names:		
Name:	. Surname:	Surname:		
Address:	. DOB:	Address:		
	. Address:			
Fax Number:Bevacizumab - continued		Fax Number:		
Initial application — advanced or metastatic of Applications from any relevant practitioner. Appr Prerequisites(tick boxes where appropriate)				
The patient has FIGO Stag	ge IV epithelial ovarian, fallopian tube, or primary perito	oneal cancer		
The patient has previously untreated advanced (FIGO Stage IIIB or IIIC) epithelial ovarian, fallopian tube, or primary peritoneal cancer				
Debulking surgery is inappropriate or The cancer is sub-optimally debulked (maximum diameter of any gross residual disease greater than 1cm)				
and Bevacizumab to be administered at a maximum dose of 15 mg/kg every three weeks and 18 weeks concurrent treatment with chemotherapy is planned				
Renewal — advanced or metastatic ovarian cancer Current approval Number (if known):				
Initial application — Recurrent Respiratory Papillomatosis Applications from any relevant practitioner. Approvals valid for 12 months. Prerequisites(tick boxes where appropriate)				
Maximum of 6 doses				
and The patient has recurrent respira The treatment is for intra-lesiona				
Renewal — Recurrent Respiratory Papillomatosis Current approval Number (if known):				
Applications from any relevant practitioner. Approvals valid for 12 months. Prerequisites(tick boxes where appropriate)				
Maximum of 6 doses				
The treatment is for intra-lesional administration and				
There has been a reduction in surgical treatments or disease regrowth as a result of treatment				

I confirm the above details are correct and that in signing this form I understand I may be audited.

Enquiries to Ministry of Health 0800 855 066

APPLICATION FOR SUBSIDY BY SPECIAL AUTHORITY

Page 3 Form SA2453 August 2025

APPLICANT (stamp or sticker acceptable)	PATIENT NHI:	REFERRER Reg No:		
Reg No:	First Names:	First Names:		
Name:	Surname:	Surname:		
Address:	DOB:	Address:		
	Address:			
Fax Number:		Fax Number:		
Bevacizumab - continued				
Initial application — Ocular Conditions Applications from any relevant practitioner. Approvals valid without further renewal unless notified. Prerequisites(tick boxes where appropriate)				
Ocular neovascularisation				
Exudative ocular angiopathy				

I confirm the above details are correct and that in signing this form I understand I may be audited.